Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series

Basit Öğe Kaydı
dc.authoridAKKAYA, HASAN/0000-0003-0853-2549
dc.authoridYilmaz, Samet/0000-0003-4738-3478
dc.contributor.authorYilmaz, Samet
dc.contributor.authorCetinkaya, Yakup
dc.contributor.authorAkkaya, Hasan
dc.contributor.authorArisoy, Arif
dc.date.accessioned2024-11-07T13:32:24Z
dc.date.available2024-11-07T13:32:24Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractBackground Essential thrombocythaemia (ET) is defined as a myeloproliferative neoplasm with a tendency to haemorrhage and thrombosis. Acute coronary thrombosis can be observed in 1 out of 10 patients. The management of ET patients with acute coronary syndrome (ACS) is a complex clinical condition that requires close follow-up. Case summary Case-1: a 52-year-old female patient with a diagnosis of ET with Janus kinase (JAK)--2 mutation, despite using cytoreductive agents, platelet counts could not be controlled. Platelet counts started to follow a normal course with the ticagrelor treatment given after ACS. Case-2: a 49-year-old female patient who was given ticagrelor treatment after ACS was found to have JAK-2+ ET. The patient whose platelet count returned to normal after ticagrelor treatment was using a cytoreductive agent before the index event. Case-3: a 54-year-old female patient with ET without any genetic mutation. In the patient whose platelet count did not decrease despite ticagrelor treatment and cytoreductive agents given after ACS, platelet counts returned to normal with interferon therapy. Discussion Platelet counts returned to the normal range with ticagrelor treatment given after ACS in patients with JAK+ ET. Monitoring platelet reduction in JAK+ patients with P2Y12 inhibition is thought to be important for new treatment options.
dc.identifier.doi10.1093/ehjcr/ytad051
dc.identifier.issn2514-2119
dc.identifier.issue2
dc.identifier.pmid36819883
dc.identifier.scopus2-s2.0-85154605650
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1093/ehjcr/ytad051
dc.identifier.urihttps://hdl.handle.net/11480/15390
dc.identifier.volume7
dc.identifier.wosWOS:000952714700006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofEuropean Heart Journal-Case Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectEssential thrombocythaemia
dc.subjectAcute coronary syndrome
dc.subjectTicagrelor
dc.subjectJAK-STAT pathway
dc.subjectCase series
dc.titleCan platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu